Submitted by gca4001 on February 22, 2023 - 2:08pm
| Title | Rituximab pharmacokinetics in children and adolescents with de novo intermediate and advanced mature B-cell lymphoma/leukaemia: a Children's Oncology Group report. |
| Publication Type | Journal Article |
| Year of Publication | 2013 |
| Authors | Barth MJ, Goldman S, Smith L, Perkins S, Shiramizu B, Gross TG, Harrison L, Sanger W, Geyer MB, Giulino-Roth L, Cairo MS |
| Journal | Br J Haematol |
| Volume | 162 |
| Issue | 5 |
| Pagination | 678-83 |
| Date Published | 2013 Sep |
| ISSN | 1365-2141 |
| Keywords | Adolescent, Adult, Age Factors, Antibodies, Monoclonal, Murine-Derived, Antineoplastic Agents, Antineoplastic Combined Chemotherapy Protocols, Cyclophosphamide, Doxorubicin, Drug Administration Schedule, Half-Life, Humans, L-Lactate Dehydrogenase, Lymphoma, B-Cell, Methotrexate, Neoplasm Staging, Pilot Projects, Prednisone, Rituximab, Vincristine, Young Adult |
| Abstract | The ANHL01P1 trial was undertaken to determine pharmacokinetics and safety following the addition of rituximab to French-American-British/Lymphome Malins de Burkitt (FAB/LMB96) chemotherapy in 41 children and adolescents with Stage III/IV mature B-cell lymphoma/leukaemia. Patients received rituximab (375 mg/m(2) ) days -2 and 0 of two induction cycles and day 0 of two consolidation cycles. Highest peak levels were achieved following the second dose of each induction cycle [299 ± 19 and 384 ± 25 μg/ml (Group-B); 245 ± 31 and 321 ± 32 μg/ml (Group-C)] with sustained troughs and t½ of 26-29 d. Rituximab can be safely added to FAB chemotherapy with high early rituximab peak/trough levels and a long t½. |
| DOI | 10.1111/bjh.12434 |
| Alternate Journal | Br J Haematol |
| PubMed ID | 23802659 |
| PubMed Central ID | PMC3745786 |
| Grant List | R13 CA171748 / CA / NCI NIH HHS / United States U10 CA098413 / CA / NCI NIH HHS / United States U54 MD007584 / MD / NIMHD NIH HHS / United States CA98413-09 / CA / NCI NIH HHS / United States U10 CA098543 / CA / NCI NIH HHS / United States CA98543-09 / CA / NCI NIH HHS / United States |